In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models

Molecular Therapy

Volumn 25, Issue 5, 2017, Pages 1168-1186

  Yin, Chaoran ^a   Zhang, Ting ^a   Qu, Xiying ^b   Zhang, Yonggang ^a   Putatunda, Raj ^a   Xiao, Xiao ^a   Li, Fang ^a   Xiao, Weidong ^a   Zhao, Huaqing ^a   Dai, Shen ^a   Qin, Xuebin ^a   Mo, Xianming ^c   Young, Won Bin ^b   Khalili, Kamel ^a   Hu, Wenhui ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

AAV; animal models; Cas9; gene therapy; genome editing; gRNA; HIV; humanized BLT mice; Tg26 mice; viral latency

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; GUIDE RNA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; BACTERIAL PROTEIN; ENDONUCLEASE; GAG PROTEIN; OLIGONUCLEOTIDE; POL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENE EDITING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; PROVIRUS; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STEM CELL CULTURE; TRANSGENIC MOUSE; VIRUS GENOME; ANIMAL; CHEMISTRY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DEPENDOPARVOVIRUS; DISEASE MODEL; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; BACTERIAL PROTEINS; BASE SEQUENCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENDONUCLEASES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EDITING; GENETIC THERAPY; GENETIC VECTORS; GENOME, VIRAL; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROVIRUSES; RNA, GUIDE; STAPHYLOCOCCUS AUREUS;

EID: 85018762305     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.012     Document Type: Article

References (85)

1. 1 Kleinstiver, B.P., Prew, M.S., Tsai, S.Q., Topkar, V.V., Nguyen, N.T., Zheng, Z., Gonzales, A.P., Li, Z., Peterson, R.T., Yeh, J.R., et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523 (2015), 481–485.
2. 2 Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–191.
3. 3 Hastie, E., Samulski, R.J., Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success–a personal perspective. Hum. Gene Ther. 26 (2015), 257–265.
4. 4 Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., Zhang, F., In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33 (2015), 102–106.
5. 5 Zuris, J.A., Thompson, D.B., Shu, Y., Guilinger, J.P., Bessen, J.L., Hu, J.H., Maeder, M.L., Joung, J.K., Chen, Z.Y., Liu, D.R., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33 (2015), 73–80.
6. 6 Yin, H., Xue, W., Chen, S., Bogorad, R.L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P.A., Jacks, T., Anderson, D.G., Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32 (2014), 551–553.
7. 7 Yin, H., Song, C.Q., Dorkin, J.R., Zhu, L.J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34 (2016), 328–333.
8. 8 Manjunath, N., Yi, G., Dang, Y., Shankar, P., Newer gene editing technologies toward HIV gene therapy. Viruses 5 (2013), 2748–2766.
9. 9 Stone, D., Kiem, H.P., Jerome, K.R., Targeted gene disruption to cure HIV. Curr. Opin. HIV AIDS 8 (2013), 217–223.
10. 10 Wang, W., Ye, C., Liu, J., Zhang, D., Kimata, J.T., Zhou, P., CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE, 9, 2014, e115987.
11. 11 Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 111 (2014), 11461–11466.
12. 12 Ebina, H., Misawa, N., Kanemura, Y., Koyanagi, Y., Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep., 3, 2013, 2510.
13. 13 Liao, H.K., Gu, Y., Diaz, A., Marlett, J., Takahashi, Y., Li, M., Suzuki, K., Xu, R., Hishida, T., Chang, C.J., et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat. Commun., 6, 2015, 6413.
14. 14 Zhu, W., Lei, R., Le Duff, Y., Li, J., Guo, F., Wainberg, M.A., Liang, C., The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology, 12, 2015, 22.
15. 15 Kaminski, R., Chen, Y., Fischer, T., Tedaldi, E., Napoli, A., Zhang, Y., Karn, J., Hu, W., Khalili, K., Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci. Rep., 6, 2016, 22555.
16. 16 Yin, C., Zhang, T., Li, F., Yang, F., Putatunda, R., Young, W.B., Khalili, K., Hu, W., Zhang, Y., Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS 30 (2016), 1163–1174.
17. 17 Kaminski, R., Bella, R., Yin, C., Otte, J., Ferrante, P., Gendelman, H.E., Li, H., Booze, R., Gordon, J., Hu, W., Khalili, K., Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther. 23 (2016), 690–695.
18. 18 Rabinovich, B.A., Ye, Y., Etto, T., Chen, J.Q., Levitsky, H.I., Overwijk, W.W., Cooper, L.J., Gelovani, J., Hwu, P., Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc. Natl. Acad. Sci. USA 105 (2008), 14342–14346.
19. 19 Potash, M.J., Chao, W., Bentsman, G., Paris, N., Saini, M., Nitkiewicz, J., Belem, P., Sharer, L., Brooks, A.I., Volsky, D.J., A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc. Natl. Acad. Sci. USA 102 (2005), 3760–3765.
20. 20 Khalili, K., Kaminski, R., Gordon, J., Cosentino, L., Hu, W., Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J. Neurovirol. 21 (2015), 310–321.
21. 21 Nishimasu, H., Cong, L., Yan, W.X., Ran, F.A., Zetsche, B., Li, Y., Kurabayashi, A., Ishitani, R., Zhang, F., Nureki, O., Crystal structure of Staphylococcus aureus Cas9. Cell 162 (2015), 1113–1126.
22. 22 Friedland, A.E., Baral, R., Singhal, P., Loveluck, K., Shen, S., Sanchez, M., Marco, E., Gotta, G.M., Maeder, M.L., Kennedy, E.M., et al. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol., 16, 2015, 257.
23. 23 Wu, Z., Yang, H., Colosi, P., Effect of genome size on AAV vector packaging. Mol. Ther. 18 (2010), 80–86.
24. 24 Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S.R., Maguire, A., Rex, T.S., Di Vicino, U., et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invest. 118 (2008), 1955–1964.
25. 25 Grieger, J.C., Samulski, R.J., Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J. Virol. 79 (2005), 9933–9944.
26. 26 Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K.A., Warrington, K.H., Srivastava, A., Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum. Gene Ther. 18 (2007), 171–182.
27. 27 Grimm, D., Lee, J.S., Wang, L., Desai, T., Akache, B., Storm, T.A., Kay, M.A., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008), 5887–5911.
28. 28 Bartel, M., Schaffer, D., Büning, H., Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front. Microbiol., 2, 2011, 204.
29. 29 Dickie, P., Felser, J., Eckhaus, M., Bryant, J., Silver, J., Marinos, N., Notkins, A.L., HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185 (1991), 109–119.
30. 30 Kopp, J.B., Klotman, M.E., Adler, S.H., Bruggeman, L.A., Dickie, P., Marinos, N.J., Eckhaus, M., Bryant, J.L., Notkins, A.L., Klotman, P.E., Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc. Natl. Acad. Sci. USA 89 (1992), 1577–1581.
31. 31 Haque, S., Lan, X., Wen, H., Lederman, R., Chawla, A., Attia, M., Bongu, R.P., Husain, M., Mikulak, J., Saleem, M.A., et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy. Am. J. Pathol. 186 (2016), 347–358.
32. 32 Cheung, J.Y., Gordon, J., Wang, J., Song, J., Zhang, X.Q., Tilley, D.G., Gao, E., Koch, W.J., Rabinowitz, J., Klotman, P.E., et al. Cardiac dysfunction in HIV-1 transgenic mouse: role of stress and BAG3. Clin. Transl. Sci. 8 (2015), 305–310.
33. 33 Hahn, Y.K., Podhaizer, E.M., Hauser, K.F., Knapp, P.E., HIV-1 alters neural and glial progenitor cell dynamics in the central nervous system: coordinated response to opiates during maturation. Glia 60 (2012), 1871–1887.
34. 34 Das, S., Basu, A., Viral infection and neural stem/progenitor cell's fate: implications in brain development and neurological disorders. Neurochem. Int. 59 (2011), 357–366.
35. 35 Mishra, M., Taneja, M., Malik, S., Khalique, H., Seth, P., Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in NeuroAIDS. J. Neurovirol. 16 (2010), 355–367.
36. 36 Rothenaigner, I., Kramer, S., Ziegler, M., Wolff, H., Kleinschmidt, A., Brack-Werner, R., Long-term HIV-1 infection of neural progenitor populations. AIDS 21 (2007), 2271–2281.
37. 37 Schwartz, L., Civitello, L., Dunn-Pirio, A., Ryschkewitsch, S., Berry, E., Cavert, W., Kinzel, N., Lawrence, D.M., Hazra, R., Major, E.O., Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J. Neurovirol. 13 (2007), 274–283.
38. 38 Fatima, M., Kumari, R., Schwamborn, J.C., Mahadevan, A., Shankar, S.K., Raja, R., Seth, P., Tripartite containing motif 32 modulates proliferation of human neural precursor cells in HIV-1 neurodegeneration. Cell Death Differ. 23 (2016), 776–786.
39. 39 Schneider, M., Tigges, B., Meggendorfer, M., Helfer, M., Ziegenhain, C., Brack-Werner, R., A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain. AIDS 29 (2015), 1147–1159.
40. 40 Balinang, J.M., Masvekar, R.R., Hauser, K.F., Knapp, P.E., Productive infection of human neural progenitor cells by R5 tropic HIV-1: opiate co-exposure heightens infectivity and functional vulnerability. AIDS 31 (2017), 753–764.
41. 41 Mao, Y., Wang, X., Yan, R., Hu, W., Li, A., Wang, S., Li, H., Single point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivo. BMC Biotechnol., 16, 2016, 1.
42. 42 Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol. 34 (2016), 334–338.
43. 43 Holehonnur, R., Luong, J.A., Chaturvedi, D., Ho, A., Lella, S.K., Hosek, M.P., Ploski, J.E., Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala. BMC Neurosci., 15, 2014, 28.
44. 44 Tsai, S.Q., Zheng, Z., Nguyen, N.T., Liebers, M., Topkar, V.V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A.J., Le, L.P., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33 (2015), 187–197.
45. 45 Frock, R.L., Hu, J., Meyers, R.M., Ho, Y.J., Kii, E., Alt, F.W., Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 33 (2015), 179–186.
46. 46 Smith, C., Gore, A., Yan, W., Abalde-Atristain, L., Li, Z., He, C., Wang, Y., Brodsky, R.A., Zhang, K., Cheng, L., Ye, Z., Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15 (2014), 12–13.
47. 47 Veres, A., Gosis, B.S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C.A., Talkowski, M.E., Musunuru, K., Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15 (2014), 27–30.
48. 48 Zhang, Y., Yin, C., Zhang, T., Li, F., Yang, W., Kaminski, R., Fagan, P.R., Putatunda, R., Young, W.B., Khalili, K., Hu, W., CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci. Rep., 5, 2015, 16277.
49. 49 Kelschenbach, J.L., Saini, M., Hadas, E., Gu, C.J., Chao, W., Bentsman, G., Hong, J.P., Hanke, T., Sharer, L.R., Potash, M.J., et al. Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV. J. Neuroimmune Pharmacol 7 (2012), 380–387.
50. 50 Song, J., Cai, Z., White, A.G., Jin, T., Wang, X., Kadayakkara, D., Anderson, C.J., Ambrose, Z., Young, W.B., Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging. J. Gen. Virol. 96 (2015), 3131–3142.
51. 51 Fuchs, S.P., Desrosiers, R.C., Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol. Ther. Methods Clin. Dev., 3, 2016, 16068.
52. 52 Brady, J.M., Baltimore, D., Balazs, A.B., Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol. Rev. 275 (2017), 324–333.
53. 53 Wang, Z., Pan, Q., Gendron, P., Zhu, W., Guo, F., Cen, S., Wainberg, M.A., Liang, C., CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep. 15 (2016), 481–489.
54. 54 Wang, G., Zhao, N., Berkhout, B., Das, A.T., CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol. Ther. 24 (2016), 522–526.
55. 55 Bauer, D.E., Canver, M.C., Orkin, S.H., Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9. J. Vis. Exp., 95, 2015, e52118.
56. 56 Peng, J., Zhou, Y., Zhu, S., Wei, W., High-throughput screens in mammalian cells using the CRISPR-Cas9 system. FEBS J. 282 (2015), 2089–2096.
57. 57 Kabadi, A.M., Ousterout, D.G., Hilton, I.B., Gersbach, C.A., Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res., 42, 2014, e147.
58. 58 Rothe, M., Schambach, A., Biasco, L., Safety of gene therapy: new insights to a puzzling case. Curr. Gene Ther. 14 (2014), 429–436.
59. 59 Mingozzi, F., High, K.A., Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
60. 60 Moser, R.J., Hirsch, M.L., AAV vectorization of DSB-mediated gene editing technologies. Curr. Gene Ther. 16 (2016), 207–219.
61. 61 Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O., Eisenhaure, T.M., Jovanovic, M., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159 (2014), 440–455.
62. 62 Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A.K., Börner, K., Grimm, D., CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol. J. 9 (2014), 1402–1412.
63. 63 Howes, R., Schofield, C., Genome engineering using adeno-associated virus (AAV). Methods Mol. Biol. 1239 (2015), 75–103.
64. 64 Hung, S.S., Chrysostomou, V., Li, F., Lim, J.K., Wang, J.H., Powell, J.E., Tu, L., Daniszewski, M., Lo, C., Wong, R.C., et al. AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo. Invest. Ophthalmol. Vis. Sci. 57 (2016), 3470–3476.
65. 65 Wright, A.V., Sternberg, S.H., Taylor, D.W., Staahl, B.T., Bardales, J.A., Kornfeld, J.E., Doudna, J.A., Rational design of a split-Cas9 enzyme complex. Proc. Natl. Acad. Sci. USA 112 (2015), 2984–2989.
66. 66 Zetsche, B., Volz, S.E., Zhang, F., A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33 (2015), 139–142.
67. 67 Nguyen, D.P., Miyaoka, Y., Gilbert, L.A., Mayerl, S.J., Lee, B.H., Weissman, J.S., Conklin, B.R., Wells, J.A., Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity. Nat. Commun., 7, 2016, 12009.
68. 68 Nuñez, J.K., Harrington, L.B., Doudna, J.A., Chemical and biophysical modulation of Cas9 for tunable genome engineering. ACS Chem. Biol. 11 (2016), 681–688.
69. 69 Fine, E.J., Appleton, C.M., White, D.E., Brown, M.T., Deshmukh, H., Kemp, M.L., Bao, G., Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Sci. Rep., 5, 2015, 10777.
70. 70 Nissim, L., Perli, S.D., Fridkin, A., Perez-Pinera, P., Lu, T.K., Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol. Cell 54 (2014), 698–710.
71. 71 Gao, Y., Zhao, Y., Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing. J. Integr. Plant Biol. 56 (2014), 343–349.
72. 72 Sakuma, T., Nishikawa, A., Kume, S., Chayama, K., Yamamoto, T., Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci. Rep., 4, 2014, 5400.
73. 73 Denton, P.W., Olesen, R., Choudhary, S.K., Archin, N.M., Wahl, A., Swanson, M.D., Chateau, M., Nochi, T., Krisko, J.F., Spagnuolo, R.A., et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86 (2012), 630–634.
74. 74 Wang, M., Zuris, J.A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc. Natl. Acad. Sci. USA 113 (2016), 2868–2873.
75. 75 Sun, W., Ji, W., Hall, J.M., Hu, Q., Wang, C., Beisel, C.L., Gu, Z., Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. Engl. 54 (2015), 12029–12033.
76. 76 Hu, P., Li, Y., Sands, M.S., McCown, T., Kafri, T., Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors. Mol. Ther. Methods Clin. Dev., 2, 2015, 15025.
77. 77 Yu, X., Liang, X., Xie, H., Kumar, S., Ravinder, N., Potter, J., de Mollerat du Jeu, X., Chesnut, J.D., Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. Biotechnol. Lett. 38 (2016), 919–929.
78. 78 Tycko, J., Myer, V.E., Hsu, P.D., Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol. Cell 63 (2016), 355–370.
79. 79 Kleinstiver, B.P., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Topkar, V.V., Zheng, Z., Joung, J.K., Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 33 (2015), 1293–1298.
80. 80 Kim, D., Kim, S., Kim, S., Park, J., Kim, J.S., Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res. 26 (2016), 406–415.
81. 81 Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H.R., Hwang, J., Kim, J.I., Kim, J.S., Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 12 (2015), 237–243.
82. 82 Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C.B., Zapatka, M., Northcott, P.A., Schramm, K., Belic, J., Jones, D.T., Tschida, B., Moriarity, B., et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat. Commun., 6, 2015, 7391.
83. 83 Yang, L., Grishin, D., Wang, G., Aach, J., Zhang, C.Z., Chari, R., Homsy, J., Cai, X., Zhao, Y., Fan, J.B., et al. Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. Nat. Commun., 5, 2014, 5507.
84. 84 Zolotukhin, S., Byrne, B.J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R.J., Muzyczka, N., Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6 (1999), 973–985.
85. 85 al Yacoub, N., Romanowska, M., Haritonova, N., Foerster, J., Optimized production and concentration of lentiviral vectors containing large inserts. J. Gene Med. 9 (2007), 579–584.